Josep Redon

Prof. Josep Redon

orcid

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2018 in European Heart Journal
Verified
Journal Article
Closed access
BWBryan Williams
Bryan Williams
GMGiuseppe Mancia
Giuseppe Mancia
WSWilko Spiering
Wilko Spiering
EREnrico Agabiti Rosei
Enrico Agabiti Rosei
MAMichel Azizi
Michel Azizi
SESerap Erdine
Serap Erdine

1 December 2017 in The Lancet
Verified
Journal Article
Open access
LALeandra Abarca-Gómez
Leandra Abarca-Gómez
ZAZiad A Abdeen
Ziad A Abdeen
ZHZargar Abdul Hamid
Zargar Abdul Hamid
NANiveen M Abu-Rmeileh
Niveen M Abu-Rmeileh
BABenjamin Acosta-Cazares
Benjamin Acosta-Cazares
MEMajid Ezzati
Majid Ezzati
Underweight, overweight, and obesity in childhood and adolescence are associated with adverse health consequences throughout the life-course. Our aim was to estimate worldwide trends in mean body-mass index (BMI) and a comprehensive set of BMI categories that cover underweight to obesity in children and adolescents, and to compare trends with those of adults. We pooled 2416 population-based studies with measurements of height and weight on 128·9 million participants aged 5 years and older, including 31·5 million aged 5-19 years. We used a Bayesian hierarchical model to estimate trends from 1975 to 2016 in 200 countries for mean BMI and for prevalence of BMI in the following categories for children and adolescents aged 5-19 years: more than 2 SD below the median of the WHO growth reference for children and adolescents (referred to as moderate and severe underweight hereafter), 2 SD to more than 1 SD below the median (mild underweight), 1 SD below the median to 1 SD above the median (healthy weight), more than 1 SD to 2 SD above the median (overweight but not obese), and more than 2 SD above the median (obesity). Regional change in age-standardised mean BMI in girls from 1975 to 2016 ranged from virtually no change (-0·01 kg/m2 per decade; 95% credible interval -0·42 to 0·39, posterior probability [PP] of the observed decrease being a true decrease=0·5098) in eastern Europe to an increase of 1·00 kg/m2 per decade (0·69-1·35, PP>0·9999) in central Latin America and an increase of 0·95 kg/m2 per decade (0·64-1·25, PP>0·9999) in Polynesia and Micronesia. The range for boys was from a non-significant increase of 0·09 kg/m2 per decade (-0·33 to 0·49, PP=0·6926) in eastern Europe to an increase of 0·77 kg/m2 per decade (0·50-1·06, PP>0·9999) in Polynesia and Micronesia. Trends in mean BMI have recently flattened in northwestern Europe and the high-income English-speaking and Asia-Pacific regions for both sexes, southwestern Europe for boys, and central and Andean Latin America for girls. By contrast, the rise in BMI has accelerated in east and south Asia for both sexes, and southeast Asia for boys. Global age-standardised prevalence of obesity increased from 0·7% (0·4-1·2) in 1975 to 5·6% (4·8-6·5) in 2016 in girls, and from 0·9% (0·5-1·3) in 1975 to 7·8% (6·7-9·1) in 2016 in boys; the prevalence of moderate and severe underweight decreased from 9·2% (6·0-12·9) in 1975 to 8·4% (6·8-10·1) in 2016 in girls and from 14·8% (10·4-19·5) in 1975 to 12·4% (10·3-14·5) in 2016 in boys. Prevalence of moderate and severe underweight was highest in India, at 22·7% (16·7-29·6) among girls and 30·7% (23·5-38·0) among boys. Prevalence of obesity was more than 30% in girls in Nauru, the Cook Islands, and Palau; and boys in the Cook Islands, Nauru, Palau, Niue, and American Samoa in 2016. Prevalence of obesity was about 20% or more in several countries in Polynesia and Micronesia, the Middle East and north Africa, the Caribbean, and the USA. In 2016, 75 (44-117) million girls and 117 (70-178) million boys worldwide were moderately or severely underweight. In the same year, 50 (24-89) million girls and 74 (39-125) million boys worldwide were obese. The rising trends in children's and adolescents' BMI have plateaued in many high-income countries, albeit at high levels, but have accelerated in parts of Asia, with trends no longer correlated with those of adults. Wellcome Trust, AstraZeneca Young Health Programme.

23 May 2016 in European Heart Journal
Verified
Journal Article
Open access
PDF file
MPMassimo F. Piepoli
Massimo F. Piepoli
AHArno W. Hoes
Arno W. Hoes
SAStefan Agewall
Stefan Agewall
CAChristian Albus
Christian Albus
Carlos BrotonsCarlos Brotons
Carlos Brotons
SBSimone Binno
Simone Binno
Cardiovascular disease (CVD) prevention is defined as a coordinated set ofactions, at the population level or targeted at an individual, that are aimed ateliminating or minimizing the impact of CVDs and their relateddisabilities.1CVD remains a leading cause of morbidity and mortality, despite improvements inoutcomes. Age-adjusted coronary artery disease (CAD) mortality has declinedsince the 1980s, particularly in high-income regions.2 CAD rates are now less than half what theywere in the early 1980s in many countries in Europe, due to preventive measuresincluding the success of smoking legislation. However, inequalities betweencountries persist and many risk factors, particularly obesity3 and diabetes mellitus(DM),4 have beenincreasing substantially. If prevention was practised as instructed it wouldmarkedly reduce the prevalence of CVD. It is thus not only prevailing riskfactors that are of concern, but poor implementation of preventive measures aswell.5,6 Prevention should bedelivered (i) at the general population level by promoting healthy lifestylebehaviour7 and(ii) at the individual level, i.e. in those subjects at moderate to high risk ofCVD or patients with established CVD, by tackling unhealthy lifestyles (e.g.poor-quality diet, physical inactivity, smoking) and by optimising risk factors.Prevention is effective: the elimination of health risk behaviours would make itpossible to prevent at least 80% of CVDs and even 40% of cancers.8,9

1 July 2013 in Journal Of Hypertension
Verified
Journal Article
Open access
GMGiuseppe Mancia
Giuseppe Mancia
RFRobert Fagard
Robert Fagard
KNKrzysztof Narkiewicz
Krzysztof Narkiewicz
JRJosep Redon
Josep Redon
AZAlberto Zanchetti
Alberto Zanchetti
FZFaiez Zannad
Faiez Zannad
Because of new evidence on several diagnostic and therapeutic aspects of hypertension, the present guidelines differ in many respects from the previous ones. Some of the most important differences are listed below: 1. Epidemiological data on hypertension and BP control in Europe. 2. Strengthening of the prognostic value of home blood pressure monitoring (HBPM) and of its role for diagnosis and management of hypertension, next to ambulatory blood pressure monitoring (ABPM). 3. Update of the prognostic significance of night-time BP, white-coat hypertension and masked hypertension. 4. Re-emphasis on integration of BP, cardiovascular (CV) risk factors, asymptomatic organ damage (OD) and clinical complications for total CV risk assessment. 5. Update of the prognostic significance of asymptomatic OD, including heart, blood vessels, kidney, eye and brain. 6. Reconsideration of the risk of overweight and target body mass index (BMI) in hypertension. 7. Hypertension in young people. 8. Initiation of antihypertensive treatment. More evidence-based criteria and no drug treatment of high normal BP. 9. Target BP for treatment. More evidence-based criteria and unified target systolic blood pressure (SBP) (<140 mmHg) in both higher and lower CV risk patients. 10. Liberal approach to initial monotherapy, without any all-ranking purpose. 11. Revised schema for priorital two-drug combinations. 12. New therapeutic algorithms for achieving target BP. 13. Extended section on therapeutic strategies in special conditions. 14. Revised recommendations on treatment of hypertension in the elderly. 15. Drug treatment of octogenarians. 16. Special attention to resistant hypertension and new treatment approaches. 17. Increased attention to OD-guided therapy. 18. New approaches to chronic management of hypertensive diseas

1 October 2018 in Journal Of Hypertension
Verified
Journal Article
Closed access
BWBryan Williams
Bryan Williams
GMGiuseppe Mancia
Giuseppe Mancia
WSWilko Spiering
Wilko Spiering
EREnrico Agabiti Rosei
Enrico Agabiti Rosei
MAMichel Azizi
Michel Azizi
IDIleana Desormais
Ileana Desormais
Document reviewers: Guy De Backer (ESC Review Co-ordinator) (Belgium), Anthony M. Heagerty (ESH Review Co-ordinator) (UK), Stefan Agewall (Norway), Murielle Bochud (Switzerland), Claudio Borghi (Italy), Pierre Boutouyrie (France), Jana Brguljan (Slovenia), Héctor Bueno (Spain), Enrico G. Caiani (Italy), Bo Carlberg (Sweden), Neil Chapman (UK), Renata Cifkova (Czech Republic), John G. F. Cleland (UK), Jean-Philippe Collet (France), Ioan Mircea Coman (Romania), Peter W. de Leeuw (The Netherlands), Victoria Delgado (The Netherlands), Paul Dendale (Belgium), Hans-Christoph Diener (Germany), Maria Dorobantu (Romania), Robert Fagard (Belgium), Csaba Farsang (Hungary), Marc Ferrini (France), Ian M. Graham (Ireland), Guido Grassi (Italy), Hermann Haller (Germany), F. D. Richard Hobbs (UK), Bojan Jelakovic (Croatia), Catriona Jennings (UK), Hugo A. Katus (Germany), Abraham A. Kroon (The Netherlands), Christophe Leclercq (France), Dragan Lovic (Serbia), Empar Lurbe (Spain), Athanasios J. Manolis (Greece), Theresa A. McDonagh (UK), Franz Messerli (Switzerland), Maria Lorenza Muiesan (Italy), Uwe Nixdorff (Germany), Michael Hecht Olsen (Denmark), Gianfranco Parati (Italy), Joep Perk (Sweden), Massimo Francesco Piepoli (Italy), Jorge Polonia (Portugal), Piotr Ponikowski (Poland), Dimitrios J. Richter (Greece), Stefano F. Rimoldi (Switzerland), Marco Roffi (Switzerland), Naveed Sattar (UK), Petar M. Seferovic (Serbia), Iain A. Simpson (UK), Miguel Sousa-Uva (Portugal), Alice V. Stanton (Ireland), Philippe van de Borne (Belgium), Panos Vardas (Greece), Massimo Volpe (Italy), Sven Wassmann (Germany), Stephan Windecker (Switzerland), Jose Luis Zamorano (Spain). The disclosure forms of all experts involved in the development of these Guidelines are available on the ESC website www.escardio.org/guidelines

1 October 2018 in The Lancet
Verified
Journal Article
Closed access
JGJennifer B Green
Jennifer B Green
SJSalim Janmohamed
Salim Janmohamed
NJNigel P Jones
Nigel P Jones
ARAnne E Rosenberg
Anne E Rosenberg
KSKristina N Sigmon
Kristina N Sigmon
TMTrisha Mandal
Trisha Mandal